SCHEMBL22290249

SCHEMBL22290249

Nc1nc(-c2cc(F)cc(Br)c2)cs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.58
ALDH1A1 P00352 10/20 0.58
MAPT P10636 7/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
KDM4E B2RXH2 4/20 0.58
HPGD P15428 2/20 0.58
HK1 P19367 1/20 0.58
HKDC1 Q2TB90 1/20 0.58
ALOX5 P09917 1/20 0.56
NPC1 O15118 8/20 0.54
SMN1; SMN2 Q16637 6/20 0.54
LTA4H P09960 2/20 0.49
MPL P40238 3/20 0.45
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
AR P10275 1/20 0.44
GFER P55789 1/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480736 0.87 MAPT (0.68) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL19718754 0.79 MAPT (0.58) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL18724009 0.79 ALDH1A1 (0.54) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL474188 0.77 MAPT (0.55) RAB9AALDH1A1MAPTMEN1KMT2A
Bromide SCHEMBL8360770 0.76 MAPT (0.54) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL474388 0.74 ALDH1A1 (0.58) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL6699384 0.74 MEN1 (1.00) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL10112701 0.74 RAB9A (0.60) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL1091753 0.74 ALDH1A1 (1.00) RAB9AALDH1A1MAPTMEN1KMT2A
Bromide SCHEMBL8357467 0.72 ALDH1A1 (0.97) RAB9AALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 CN disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RAB9A 572/4885ALDH1A1 2571/4885MAPT 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.